GW Henssler & Associates Ltd. Invests $15.29 Million in IDEXX Laboratories, Inc. $IDXX

Key Points

• GW Henssler & Associates Ltd. has purchased 36,420 shares of IDEXX Laboratories, Inc., valued at approximately $15,294,000, marking a significant investment during the 1st quarter.
• IDEXX Laboratories reported a quarterly earnings per share (EPS) of $3.63, exceeding analyst estimates by $0.35, with revenue of $1.11 billion for the quarter.
• Institutional investors own 87.84% of IDEXX Laboratories' stock, indicating strong institutional support for the company.

GW Henssler & Associates Ltd. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 36,420 shares of the company's stock, valued at approximately $15,294,000.

Other hedge funds have also bought and sold shares of the company. Sage Mountain Advisors LLC raised its holdings in IDEXX Laboratories by 3.8% in the first quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock worth $267,000 after buying an additional 23 shares during the last quarter. PDS Planning Inc raised its holdings in IDEXX Laboratories by 3.9% in the first quarter. PDS Planning Inc now owns 641 shares of the company's stock worth $269,000 after buying an additional 24 shares during the last quarter. King Luther Capital Management Corp raised its holdings in IDEXX Laboratories by 0.5% in the first quarter. King Luther Capital Management Corp now owns 4,896 shares of the company's stock worth $2,056,000 after buying an additional 24 shares during the last quarter. Bigelow Investment Advisors LLC raised its holdings in IDEXX Laboratories by 1.9% in the first quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock worth $596,000 after buying an additional 27 shares during the last quarter. Finally, Wedbush Securities Inc. raised its holdings in IDEXX Laboratories by 1.3% in the first quarter. Wedbush Securities Inc. now owns 2,145 shares of the company's stock worth $901,000 after buying an additional 28 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded up $6.49 during trading hours on Thursday, hitting $640.44. 440,527 shares of the company's stock traded hands, compared to its average volume of 706,554. The business's fifty day moving average price is $588.74 and its two-hundred day moving average price is $504.04. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $51.24 billion, a P/E ratio of 53.33, a P/E/G ratio of 4.19 and a beta of 1.56. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the business posted $2.44 earnings per share. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent analyst reports. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. BTIG Research boosted their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Piper Sandler reissued a "neutral" rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a report on Monday, August 4th. Finally, Leerink Partners boosted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $649.44.

Insider Transactions at IDEXX Laboratories

In related news, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. The trade was a 46.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 2,187 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director directly owned 262 shares of the company's stock, valued at $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,057 shares of company stock valued at $34,293,468. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.